Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1476875
This article is part of the Research Topic Immune System Interactions in Hematological Tumor Microenvironments: Pathways to Innovative Treatments View all 5 articles

Chemo-free Salvage Treatment Outperforms Traditional Chemotherapy in Advanced Lines of Relapsed/Refractory Subcutaneous Panniculitis-like T-cell Lymphoma

Provisionally accepted
Chao Chen Chao Chen 1Jingjing Yin Jingjing Yin 2Wei Wang Wei Wang 1Danqing Zhao Danqing Zhao 1Chong Wei Chong Wei 1Congwei Jia Congwei Jia 3Wei Zhang Wei Zhang 1Daobin Zhou Daobin Zhou 1Yan Zhang Yan Zhang 1*
  • 1 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
  • 2 Department of Hematology, Beijing Hospital, Beijing, China
  • 3 Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

The final, formatted version of the article will be published soon.

    Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of non-Hodgkin lymphoma with a good prognosis, but the optimal treatment for relapsed/refractory (R/R) SPTCL has been rarely discussed. This study aims to compare the efficacy of conventional chemotherapy and chemo-free immunomodulatory regimen for R/R SPTCL. We retrospectively reviewed the patients with first relapse or primary refractory SPTCL between September 1997 and October 2020. A total of 19 patients with R/R SPTCL with a median age of 34 were included. All patient received the first-line chemotherapy-based treatment with a median PFS of 1.8 months. In these patients, 16 received salvage second-line treatment with an ORR of 31.3% and a median TTNT of 3.0 months. 13 of these 16 patients received chemotherapy-based treatment, resulting in a median TTNT of 2.4 months. 2 of these 16 patients received allogeneic hematopoietic stem cell transplantation and achieved long term complete remission (CR). In third-line treatment, 7 patients received chemotherapy-based regimen and 6 received chemo-free regimen such as VRMP (bortezomib, lenadomide and methylprednisolone) regimen and CsA plus IFNα regimen. The median TTNT of chemotherapy and chemo-free group were 3.2 months and not reached, respectively. Chemo-free group had a better TTNT than chemotherapy group (p=0.007). The use of chemotherapy-free regimens for R/R SPTCL appears promising and warrants further validation.

    Keywords: Subcutaneous panniculitis-like T-cell lymphoma, chemo-free regimen, Chemothearpy, Immunotharapy, T-cell lymphoma

    Received: 06 Aug 2024; Accepted: 21 Nov 2024.

    Copyright: © 2024 Chen, Yin, Wang, Zhao, Wei, Jia, Zhang, Zhou and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yan Zhang, Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.